.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent research suggests that vardenafil and glutamatergic transmission have a significant link in cognitive health. Memory and synaptic plasticity depend heavily on cyclic guanosine monophosphate (cGMP) signaling. Phosphodiesterase 5 (PDE5) inhibitors like vardenafil (VDF) elevate these intracellular cGMP levels. Consequently, clinicians investigate these drugs for treating cognitive disorders such as Alzheimer's disease (AD).
A study recently identified the specific signaling pathways connecting PDE5 inhibition to excitatory synaptic transmission. The researchers showed that VDF activates a pathway involving amyloid-beta (Aβ) and cellular prion protein (PrP). Specifically, VDF increases Aβ levels, which then reduces PrP surface exposure. Blocking Aβ production prevents this effect. Moreover, the study demonstrates that PrP facilitates Aβ internalization. This interaction suggests a dynamic coupling between the trafficking of these two proteins.
Functionally, VDF selectively augments presynaptic excitatory transmission. Increased VGLUT1 puncta density and elevated miniature excitatory postsynaptic current (mEPSC) frequency evidence this change. Importantly, the mEPSC amplitude remained unchanged during the experiments. Disrupting the interaction between Aβ and PrP abolishes these beneficial presynaptic effects. Therefore, this axis serves as a required mediator for the synaptic response to vardenafil.
These findings expand our framework of Aβ-PrP signaling. Instead of viewing Aβ strictly as a neurotoxin, we now see its context-dependent role in synaptic regulation. This discovery highlights the potential for PDE5 inhibitors to modulate brain circuits beyond their traditional uses.
Vardenafil increases cGMP levels, which enhances presynaptic glutamatergic transmission through a unique pathway involving amyloid-beta and cellular prion protein. This mechanism may support memory and synaptic plasticity.
In this specific signaling pathway, vardenafil-induced increases in amyloid-beta help regulate the surface exposure of cellular prion protein. This coupling is essential for the drug's effect on excitatory synapses.
Disclaimer: This content is for informational and educational purposes only. It is not intended as medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.
References
1. Kafi MAA et al. The PDE5 inhibitor vardenafil enhances glutamatergic transmission through amyloid-beta and cellular prion protein. Neurotherapeutics. 2026 Jun 07. doi: undefined. PMID: 42251810.
2. Kumar A, Kim F, Song DK, Choung JJ. Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders. Aging and disease. 2024; 15(5): 2008-2014. doi: 10.14336/AD.2023.1129.
3. Sanders RJ, et al. PDE5 inhibitor drugs for use in dementia. PMC - NIH. 2023 Sep 25.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Vardenafil increases presynaptic excitatory transmission through a novel Aβ-PrP signaling axis, highlighting a potential role in treating cognitive disorder...
3 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
